• Investor Home
  • Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Obesity Week 2018 Conference

Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Obesity Week 2018 Conference

Monday, November 12, 2018 5:46 pm CST

Public Company Information:

NASDAQ:
APEN

AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced its participation during Obesity Week 2018 taking place November 11-15, 2018 at The Music City Center in Nashville, Tennessee.

During the conference, Obesity Week will host several hands-on workshops including sessions that feature ORBERA® and OverStitch™ technologies. In addition the Apollo Mobile Learning Center will be in Nashville to support a series of hands-on physician training sessions. The Apollo Mobile Learning Center is a state of the art mobile training facility that allows for advanced endoscopic training. These sessions further Apollo’s mission to develop safe, effective, innovative and less-invasive solutions for bariatric and gastrointestinal therapies.

Clinical abstracts and presentations will be presented on Apollo’s ORBERA® Intragastric Balloon, the market leading intragastric balloon that now has distributed over 295,000 devices worldwide.

Apollo will also feature LAP-BAND® which recently announced a 20-year LAP-BAND study conducted by lead author Emeritus Professor Paul O’Brien and examined over 8,000 LAP-BAND patients in a single center which is believed to be the largest and longest running series of its kind in the world. Patients in the study who had LAP-BAND 20 years ago, now weigh an average of 30.1kg less than their initial weight with low revision and reoperation rates that decreased over time with improvements in surgical technique, aftercare, and the device itself.

To learn more about OverStitch™, ORBERA® and LAP-BAND®, please visit Apollo Endosurgery at booth #1119 during the conference.

About ORBERA®

ORBERA® is an incision-less, non-surgical weight loss solution designed for adult patients suffering from obesity, who are not appropriate for or considering invasive surgery, but for whom diet and exercise or pharmaceutical interventions have not worked.

In a non-surgical (endoscopic) procedure, the thin and deflated ORBERA balloon is placed into the stomach. It is then filled with saline until it’s about the size of a grapefruit. The procedure typically takes about 20 to 30 minutes and the patient can generally go home the same day. At six months, through another non-surgical procedure, the ORBERA balloon is deflated and then removed.

Once the balloon is in place, the patient receives an individually tailored support program through the ORBERA Managed Weight Loss System team of experts to help keep them motivated, coordinate their program and help them work through weight loss barriers to meet their long-term weight loss goals. Coaching takes place over 12 months, even though the balloon is removed after six months. The program is designed to help the patient develop sustainable, healthy habits that will help keep weight off over time.

For more than 20 years, the global medical community has been using intragastric balloons from the makers of ORBERA to help thousands of people lose weight. More than 295,000 ORBERA balloons have been distributed worldwide in over 70 countries.

For additional information regarding ORBERA, please visit www.orbera.com.

For full safety information please visit www.orbera.com/dfu, talk with your doctor, or call Apollo Customer Support at 1-855-MYORBERA.

About LAP-BAND®

The LAP-BAND® AP Adjustable Gastric Banding System is placed laparoscopically in a minimally invasive procedure to assist in gradual weight loss. The LAP-BAND System is fastened around the top of the stomach, and works by applying a constant, gentle pressure to this area. This gives a patient a feeling of satiety (a feeling of fullness) on a smaller amount of food, therefore, you eat less.

LAP-BAND can deliver sustained weight loss, improvements in quality of life, and reduced cardiometabolic risk when combined with reasonable and proper physician follow-up with their patient.

For additional information regarding LAP-BAND, please visit www.lapband.com.

For full safety information please talk with your doctor, or call 1-800-LAPBAND.

About OverStitch™

The OverStitch endoscopic suturing system enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures from a flexible endoscope. This new technology enables a secure approximation of tissue endoscopically and a wide range of less invasive solutions for physicians who treat defects in both the upper and lower GI tract of their patients. Additionally, physicians are leveraging endoscopic suturing to perform a variety of advanced bariatric procedures. For more information regarding OverStitch go to: www.overstitch.com.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies for the treatment of obesity, a condition facing over 650 million people globally, as well as other gastrointestinal conditions. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the ORBERA® Intragastric Balloon, and the LAP-BAND® Adjustable Gastric Banding System.

Apollo’s common stock is traded on Nasdaq Global Market under the symbol "APEN." For more information regarding Apollo, go to: www.apolloendo.com.

© 2018 Apollo Endosurgery, Inc. All rights reserved. Any third-party trademarks used herein are the property of their respective owners.

Cautionary Note on Forward-Looking Statements

Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: reports of adverse events related to our products, outcomes of clinical studies, developments in medical technology, regulatory approvals and extensive regulatory oversight by the FDA or other regulatory bodies, unfavorable media coverage related to our products or related procedures, reimbursement decisions by private or government payors, physician adoption and recommendations of procedures utilizing our products and other factors detailed from time to time in the reports Apollo files with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2017 and the Form 10-Q for the three months ended September 30, 2018. Copies of reports filed with the SEC are posted on Apollo’s website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Contact:

Apollo Endosurgery, Inc.
Media Contact:
Jen Cook, 512-279-5158
jen.cook@apolloendo.com
or
Investor Relations Contact:
John Gillings, 512-279-5100
investor-relations@apolloendo.com

Business Wire InvestorHQ℠